J. S. Berek

3.9k total citations · 2 hit papers
48 papers, 2.7k citations indexed

About

J. S. Berek is a scholar working on Reproductive Medicine, Surgery and Obstetrics and Gynecology. According to data from OpenAlex, J. S. Berek has authored 48 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Reproductive Medicine, 13 papers in Surgery and 13 papers in Obstetrics and Gynecology. Recurrent topics in J. S. Berek's work include Ovarian cancer diagnosis and treatment (34 papers), Endometrial and Cervical Cancer Treatments (12 papers) and Intraperitoneal and Appendiceal Malignancies (9 papers). J. S. Berek is often cited by papers focused on Ovarian cancer diagnosis and treatment (34 papers), Endometrial and Cervical Cancer Treatments (12 papers) and Intraperitoneal and Appendiceal Malignancies (9 papers). J. S. Berek collaborates with scholars based in United States, Spain and Denmark. J. S. Berek's co-authors include Christine H. Holschneider, Neville F. Hacker, Leo D. Lagasse, Ronald S. Leuchter, Roberta K. Nieberg, Robert M. Elashoff, Thomas W. Castaldo, Alexander Sedlis, B. Bundy and Edgardo Yordan and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Obstetrics and Gynecology and Annals of Oncology.

In The Last Decade

J. S. Berek

46 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ovarian cancer: Epidemiology, biology, and prognostic factors

2000 547 citations Christine H. Holschneider, J. S. Berek Seminars in Surgical Oncology profile →
Primary cytoreductive surgery for epithelial ovarian cancer.

1983 348 citations Neville F. Hacker, J. S. Berek et al. PubMed profile →

Peers

Countries citing papers authored by J. S. Berek

Since Specialization

Citations

This map shows the geographic impact of J. S. Berek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. S. Berek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. S. Berek more than expected).

Fields of papers citing papers by J. S. Berek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. S. Berek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. S. Berek. The network helps show where J. S. Berek may publish in the future.

Co-authorship network of co-authors of J. S. Berek

This figure shows the co-authorship network connecting the top 25 collaborators of J. S. Berek. A scholar is included among the top collaborators of J. S. Berek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. S. Berek. J. S. Berek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: Results from the ENGOT-OV16/NOVA Trial 2017 ·Annals of Oncology ·(unknown), (unknown), Mansoor Raza Mirza, Lucy Gilbert, Michel Fabbro, Anna V. Tinker, (unknown), Andrés Redondo, J. S. Berek, Linn Woelber, Helen S. Pentikis, Kathleen N. Moore, Domenica Lorusso, Benedict B. Benigno, Sebastien Hazard, Philippe Follana, B.J. Rimel, Ursula A. Matulonis, Shefali Agarwal, Vikram Kansra	8
2	gynaecological cancers A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial) 2016 ·Annals of Oncology ·Mansoor Raza Mirza, Bradley J. Monk, Amit M. Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, JA Ledermann, Domenica Lorusso, Ignace Vergote, Ora Rosengarten, J. S. Berek, Jørn Herrstedt, (unknown), Andreas duBois, Antonio González-Martı́n, Philippe Follana, Benedict B. Benigno, B.J. Rimel, Shefali Agarwal, Ursula A. Matulonis	7
3	An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer 2006 ·International Journal of Gynecological Cancer ·(unknown), (unknown), J. S. Berek	38
4	Progress in ovarian cancer research: Proceedings of the 5th Biennial Ovarian Cancer Research Symposium 2006 ·International Journal of Gynecological Cancer ·ML Disis, Saul E. Rivkin, Andre T. Baron, (unknown), Denise C. Connolly, F. Ueland, Elise C. Kohn, Edward L. Trimble, J. S. Berek	2
5	FIGO stage III and IV uterine papillary serous carcinoma: Impact of residual disease on survival 2002 ·International Journal of Gynecological Cancer ·Sanaz Memarzadeh, Christine H. Holschneider, Robert E. Bristow, (unknown), Yun Fu, Beth Y. Karlan, J. S. Berek, Robin Farias‐Eisner	49
6	Ovarian cancer: Epidemiology, biology, and prognostic factors breakdown → 2000 ·Seminars in Surgical Oncology ·Christine H. Holschneider, J. S. Berek	547
7	Intraperitoneal α-Interferon Alternating with Cisplatin in Residual Ovarian Carcinoma: A Phase II Gynecologic Oncology Group Study 1999 ·Gynecologic Oncology ·J. S. Berek, Maurie Markman, John A. Blessing, Paul R. Kucera, Beth E. Nelson, Barrie Anderson, Parviz Hanjani	25
8	Endometrial cancer: recent developments in evaluation and treatment. 1999 ·PubMed ·(unknown), Kathryn F. McGonigle, J. S. Berek	14
9	Reducing Loss-to-Follow-Up Among Women With Abnormal Pap Smears 1998 ·Medical Care ·(unknown), Celia P. Kaplan, Lori A. Crane, J. S. Berek, Gerald S. Bernstein, John E. Gunning, Maureen W. McClatchey	78
10	Combination of Transforming Growth Factor β Antisense and Interleukin-2 Gene Therapy in the Murine Ovarian Teratoma Model 1998 ·Gynecologic Oncology ·Oliver Dorigo, Daniel L. Shawler, Ivor Royston, Robert E. Sobol, J. S. Berek, Habib Fakhrai	20
11	Gene therapy for ovarian cancer: development of novel treatment strategies 1997 ·International Journal of Gynecological Cancer ·Oliver Dorigo, J. S. Berek	8
12	Peritoneal adenocarcinoma (serous) of Müllerian type: a subgroup of women presenting with peritoneal carcinomatosis 1994 ·International Journal of Gynecological Cancer ·(unknown), Roberta K. Nieberg, (unknown), J. S. Berek	21
13	The Influence of Tumor Grade, Distribution, and Extent of Carcinomatosis in Minimal Residual Stage III Epithelial Ovarian Cancer after Optimal Primary Cytoreductive Surgery 1994 ·Gynecologic Oncology ·Robin Farias‐Eisner, (unknown), Michelle de Oliveira, (unknown), Beth Y. Karlan, (unknown), J. S. Berek	54
14	The influence of tumor distribution and extent of carcinomatosis in minimal residual disease after optimal primary cytoreductive surgery for epithelial ovarian cancer 1993 ·Gynecologic Oncology ·(unknown), (unknown), J. S. Berek	1
15	Prognostic Factors for Groin Node Metastasis in Squamous Cell Carcinoma of the Vulva (A Gynecologic Oncology Group Study) 1993 ·Gynecologic Oncology ·Howard D. Homesley, B. Bundy, Alexander Sedlis, Edgardo Yordan, J. S. Berek, Antoine E. Jahshan, Rodrigue Mortel	153
16	Impact of contraception on gynecologic cancers 1993 ·American Journal of Obstetrics and Gynecology ·Arthur L. Herbst, J. S. Berek	9
17	Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (A Gynecologic Oncology Group Study) 1991 ·American Journal of Obstetrics and Gynecology ·Howard D. Homesley, B. Bundy, Alexander Sedlis, Edgardo Yordan, J. S. Berek, Antoine E. Jahshan, Rodrique Mortel	230
18	Pathophysiology and management of endometrial hyperplasia and carcinoma. 1990 ·PubMed ·(unknown), Joseph C. Gambone, J. S. Berek	15
19	Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes. 1990 ·PubMed ·Alan Lichtenstein, James Berenson, Joseph Gera, K E Waldburger, Otoniel Martı́nez-Maza, J. S. Berek	53
20	Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. 1983 ·PubMed ·(unknown), Neville F. Hacker, J. S. Berek, Larry C. Ford, James D. Hoeschele, (unknown), Leo D. Lagasse	58

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact